Clinical Trial

G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.
Trial Details
NCT Number NCT07184788
Lead Sponsor Navy General Hospital, Beijing
Conditions Aggressive B-Cell Lymphoma
Enrollment 80 participants
Start Date 2025-10-01
Primary Completion 2030-10-01 (estimated)
Study Completion 2031-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-22